358 related articles for article (PubMed ID: 22867098)
1. The emerging role of histone lysine demethylases in prostate cancer.
Crea F; Sun L; Mai A; Chiang YT; Farrar WL; Danesi R; Helgason CD
Mol Cancer; 2012 Aug; 11():52. PubMed ID: 22867098
[TBL] [Abstract][Full Text] [Related]
2. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.
Björkman M; Östling P; Härmä V; Virtanen J; Mpindi JP; Rantala J; Mirtti T; Vesterinen T; Lundin M; Sankila A; Rannikko A; Kaivanto E; Kohonen P; Kallioniemi O; Nees M
Oncogene; 2012 Jul; 31(29):3444-56. PubMed ID: 22120715
[TBL] [Abstract][Full Text] [Related]
3. Histone modifications, stem cells and prostate cancer.
Crea F; Clermont PL; Mai A; Helgason CD
Curr Pharm Des; 2014; 20(11):1687-97. PubMed ID: 23888964
[TBL] [Abstract][Full Text] [Related]
4. Histone lysine demethylase inhibition reprograms prostate cancer metabolism and mechanics.
Chianese U; Papulino C; Passaro E; Evers TM; Babaei M; Toraldo A; De Marchi T; Niméus E; Carafa V; Nicoletti MM; Del Gaudio N; Iaccarino N; Randazzo A; Rotili D; Mai A; Cappabianca S; Mashaghi A; Ciardiello F; Altucci L; Benedetti R
Mol Metab; 2022 Oct; 64():101561. PubMed ID: 35944897
[TBL] [Abstract][Full Text] [Related]
5. The role and prospect of lysine-specific demethylases in cancer chemoresistance.
Song YQ; Yang GJ; Ma DL; Wang W; Leung CH
Med Res Rev; 2023 Sep; 43(5):1438-1469. PubMed ID: 37012609
[TBL] [Abstract][Full Text] [Related]
6. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
Liu Q; Pang J; Wang LA; Huang Z; Xu J; Yang X; Xie Q; Huang Y; Tang T; Tong D; Liu G; Wang L; Zhang D; Ma Q; Xiao H; Lan W; Qin J; Jiang J
J Pathol; 2021 Jan; 253(1):106-118. PubMed ID: 33009820
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analyses of prognostic biomarkers and immune infiltrates among histone lysine demethylases (KDMs) in hepatocellular carcinoma.
Qu LH; Fang Q; Yin T; Yi HM; Mei GB; Hong ZZ; Qiu XB; Zhou R; Dong HF
Cancer Immunol Immunother; 2022 Oct; 71(10):2449-2467. PubMed ID: 35254477
[TBL] [Abstract][Full Text] [Related]
8. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.
Tian X; Zhang S; Liu HM; Zhang YB; Blair CA; Mercola D; Sassone-Corsi P; Zi X
Curr Cancer Drug Targets; 2013 Jun; 13(5):558-79. PubMed ID: 23713993
[TBL] [Abstract][Full Text] [Related]
9. Lysine Demethylation in Pathogenesis.
Cao J; Yan Q
Adv Exp Med Biol; 2023; 1433():1-14. PubMed ID: 37751133
[TBL] [Abstract][Full Text] [Related]
10. KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.
Stein J; Majores M; Rohde M; Lim S; Schneider S; Krappe E; Ellinger J; Dietel M; Stephan C; Jung K; Perner S; Kristiansen G; Kirfel J
Am J Pathol; 2014 Sep; 184(9):2430-7. PubMed ID: 25016185
[TBL] [Abstract][Full Text] [Related]
11. A scintillation proximity assay for histone demethylases.
Yu W; Eram MS; Hajian T; Szykowska A; Burgess-Brown N; Vedadi M; Brown PJ
Anal Biochem; 2014 Oct; 463():54-60. PubMed ID: 25010373
[TBL] [Abstract][Full Text] [Related]
12. Assessing histone demethylase inhibitors in cells: lessons learned.
Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
[TBL] [Abstract][Full Text] [Related]
13. Targeting histone demethylases as a potential cancer therapy (Review).
Diao W; Zheng J; Li Y; Wang J; Xu S
Int J Oncol; 2022 Sep; 61(3):. PubMed ID: 35801593
[TBL] [Abstract][Full Text] [Related]
14. Targeting histone lysine demethylases - progress, challenges, and the future.
Thinnes CC; England KS; Kawamura A; Chowdhury R; Schofield CJ; Hopkinson RJ
Biochim Biophys Acta; 2014 Dec; 1839(12):1416-32. PubMed ID: 24859458
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic gene regulation by histone demethylases: emerging role in oncogenesis and inflammation.
Kang MK; Mehrazarin S; Park NH; Wang CY
Oral Dis; 2017 Sep; 23(6):709-720. PubMed ID: 27514027
[TBL] [Abstract][Full Text] [Related]
16. c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Maina PK; Shao P; Liu Q; Fazli L; Tyler S; Nasir M; Dong X; Qi HH
Oncotarget; 2016 Nov; 7(46):75585-75602. PubMed ID: 27689328
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.
Duan L; Chen YA; Liang Y; Chen Z; Lu J; Fang Y; Cao J; Lu J; Zhao H; Pong RC; Hernandez E; Kapur P; Tran TAT; Smith T; Martinez ED; Ahn JM; Hsieh JT; Luo JH; Liu ZP
Biomed Pharmacother; 2023 Feb; 158():114077. PubMed ID: 36495660
[TBL] [Abstract][Full Text] [Related]
18. The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion.
Wang J; Yu Q; Qiu Z; Dai T; Wang S; Yang X; Evers BM; Wu Y
Aging (Albany NY); 2020 Jan; 12(1):397-415. PubMed ID: 31901895
[TBL] [Abstract][Full Text] [Related]
19. Insights into the epigenetic mechanisms involving histone lysine methylation and demethylation in ischemia induced damage and repair has therapeutic implication.
Chakravarty S; Jhelum P; Bhat UA; Rajan WD; Maitra S; Pathak SS; Patel AB; Kumar A
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):152-164. PubMed ID: 27664837
[TBL] [Abstract][Full Text] [Related]
20. The Emerging Significance of Histone Lysine Demethylases as Prognostic Markers and Therapeutic Targets in Head and Neck Cancers.
Dorna D; Paluszczak J
Cells; 2022 Mar; 11(6):. PubMed ID: 35326475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
